Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05NMK
|
|||
| Former ID |
DNC000486
|
|||
| Drug Name |
CU201 (B9870)
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kininogen (KNG1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
| Syndecan-2-mediated signaling events | ||||
| Reactome | Platelet degranulation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| ACE Inhibitor Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May;8(5):1280-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.